Application Note
Modeling Alzheimer's Disease with ELISA and Off-the-Shelf Patient iPSC-Derived Neurons
Measure Alzheimer's disease biomarkers in off-the-shelf patient iPSC-derived excitatory neurons, with ELISA-confirmed elevation of Aβ42, Aβ40, total Tau, and p-Tau relative to age-matched healthy controls.
Download Your Application Note
"*" indicates required fields
We respect your inbox. You can unsubscribe at any time. View our privacy policy.
Inside This Application Note
Review ELISA biomarker data from APOE4 patient and healthy control iPSC-derived excitatory neurons cultured for up to 6 weeks, including AD phenotype confirmation and β-secretase inhibitor dose-response results.
- All four AD biomarkers — Aβ42, Aβ40, total Tau, and p-Tau — showed higher values in the AD patient line relative to the healthy control line at the end of week 6, demonstrating that iPSC-derived neurons display known phenotypes of AD
- Increasing doses of β-secretase inhibitors LY2886721 and BSI-IV resulted in a corresponding decrease of Aβ42 and Aβ40 in AD patient neuron culture supernatants after 6 weeks of culture
- Neurons sourced from CIRM-derived APOE4 carrier Alzheimer's disease patient iPSCs and differentiated using Quick Tissue™ technology, available off-the-shelf without requiring in-house iPSC reprogramming or differentiation
Related Resources
Explore related cell models, services, and protocols connected to this application.